Completed Access to Information Requests

About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Current Search

Report Type

Organization

Disposition

Year

Month

Found 783 record(s)

Req # A-2023-001014

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-107287-525.

Organization: Health Canada

44 page(s)
January 2024

Req # A-2023-001017

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-107682-242, Deputy Ministerial Meeting with Helium Developers Association of Canada.

Organization: Health Canada

4 page(s)
January 2024

Req # A-2023-001030

Adverse Drug Reactions (ADRs) for MORPHINE. Report numbers: 001051386, E2B_06578485, E2B_03703513, E2B_03967538, E2B_03707208, E2B_03707225, E2B_03967567. ADR for HEPARIN. Report number: 001051150. ADR for MIDAZOLAM. Report number: 001010623.

Organization: Health Canada

56 page(s)
January 2024

Req # A-2023-001032

Adverse Drug Reactions (ADRs) for PANTOPRAZOLE SODIUM. Report numbers: E2B_06587978, E2B_06541633, 001055161. ADRs for MESALAZINE. Report numbers: E2B_06586132, E2B_06580859, E2B_06574661, E2B_06589396, E2B_06568908, E2B_06565458, E2B_06538534.

Organization: Health Canada

1386 page(s)
January 2024

Req # A-2023-001159

Adverse Drug Reaction (ADR). Report number: 001051430.

Organization: Health Canada

4 page(s)
January 2024

Req # A-2023-001165

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-109203-330.

Organization: Health Canada

21 page(s)
January 2024

Req # A-2023-001167

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-109485-722, Deputy Ministerial Meeting with the President and Chief Executive Officer of The Ottawa Hospital.

Organization: Health Canada

6 page(s)
January 2024

Req # A-2023-001178

Adverse Drug Reaction (ADR). Report number: 001061666.

Organization: Health Canada

1 page(s)
January 2024

Req # A-2023-001198

Adverse Drug Reaction (ADR) for MORPHINE. Report number: 001060082.

Organization: Health Canada

7 page(s)
January 2024

Req # A-2023-001208

Adverse Drug Reactions (ADRs) for GAMMAGARD LIQUID. Report numbers: 001060408, 001060009, 001060372, 001060399, 001060415. ADR for MESALAMINE. Report number: 1067727.

Organization: Health Canada

24 page(s)
January 2024
Date modified: